Chardan analyst Geulah Livshits lowered the firm’s price target on Editas Medicine to $22 from $35 and keeps a Buy rating on the shares following the fiscal 2022 results. Editas reiterated guidance for a mid-23 data update on ex vivo gene-edited hematopoietic stem cell therapy EDIT-301 for sickle cell disease, the analyst tells investors in a research note. The firm says Editas "is in the midst of a retrenching" after discontinuing internal investments in inherited retinal diseases and its preclinical iNK programs.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine price target lowered to $30 from $36 at Wells Fargo
- Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
- Editas Medicine reports Q4 EPS (88c), consensus (80c)
- Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
- Editas Medicine initiated with an Overweight at Cantor Fitzgerald
